Results 51 to 60 of about 734,056 (162)

Toxic Epidermal Necrolysis: Reply [PDF]

open access: yesMedical Journal Armed Forces India, 2007
Dear Editor, The authors wish to thank the reader for the keen interest shown in the article and for his compliments. We would like to clarify the issues raised by him. Toxic Epidermal Necrolysis (TEN) has been reported to develop due to corticosteroids as well as in spite of steroid therapy [1].
N, Kumar, N S, Walia
openaire   +2 more sources

Safety of proton pump inhibitors in children: A systematic review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim To systematically evaluate the safety of proton pump inhibitor (PPI) therapy in children aged 0–12 years, with a focus on treatment‐emergent adverse events across different study designs and age groups. Method The systematic review was carried out according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA ...
Ahmad Raza Sachel   +2 more
wiley   +1 more source

Toxic epidermal necrolysis following a furosemide injection: a case report

open access: yesJournal of Medical Case Reports
Background Toxic epidermal necrolysis is a life threatening adverse cutaneous reaction mostly following drug administration. It is characterized by extensive detachment of skin and mucous membranes with a more than 30% total body surface area involvement.
Clare Nakubulwa   +2 more
doaj   +1 more source

Ciprofloxacin induced toxic epidermal necrolysis with cholestatic hepatitis: A case report with literature review and revisit to the Naranjo adverse drug reaction probability scale

open access: yesClinical Case Reports, 2022
Ciprofloxacin, among the many Fluoroquinolones, has been widely used as a broad‐spectrum antibiotic due to its wide range of action and relatively safe adverse effect profile.
Bishal Dhakal   +7 more
doaj   +1 more source

Pembrolizumab‐Induced Subacute Cutaneous Lupus Erythematosus: A Case Report

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Subacute cutaneous lupus erythematosus (SCLE) is an increasingly recognized cutaneous immune‐related adverse event of immune checkpoint inhibitors. We report an 83‐year‐old woman who developed pruritic annular and polycyclic plaques 10 weeks after starting pembrolizumab for oropharyngeal squamous cell carcinoma.
Sebastiano Posenato   +5 more
wiley   +1 more source

Clinical and Demographic Predictors of In‐Hospital Mortality in Adult SJS/TEN Hospitalizations: A National Inpatient Sample Analysis 2017–2022

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Stevens−Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe mucocutaneous reactions associated with significant morbidity and mortality. Published studies have identified a limited number of variables predictive of death, but their description of acute complications is sparse.
Damilola Oladinni   +2 more
wiley   +1 more source

Important Points in Toxic Epidermal Necrolysis Management

open access: yesOman Medical Journal, 2019
There are several important points that the authors did not highlight which are critical and form the cornerstones in the care of patients with possible TEN.
Sultan
doaj   +1 more source

Epidermal necrolysis: SCORTEN performance in AIDS and non-AIDS patients [PDF]

open access: yesAnais Brasileiros de Dermatologia, 2019
: Background: Stevens-Johnson syndrome and toxic epidermal necrolysis are life-threatening blistering drug reactions with high incidence of ocular sequela.
Carlos Gustavo Wambier   +8 more
doaj   +1 more source

Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis, A Review of Pathogenesis, Clinical Features, Diagnosis and Treatment

open access: yesJournal of Education, Health and Sport, 2022
Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare, acute conditions, potentially life-threatening, immune-mediated and often unpredictable.
Martyna Rozenbajgier   +3 more
doaj   +1 more source

Updated EAACI Statement on Drug Hypersensitivity Skin Testing: Methodology and Non‐Irritative Concentrations

open access: yesAllergy, EarlyView.
ABSTRACT These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non‐immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4–6 weeks post‐reaction; whereas beyond 6 months, false‐negative results increase.
Annick Barbaud   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy